Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.

@article{Wang2012EffectOL,
  title={Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.},
  author={Jianmiao Wang and Bin En Nie and Weining Xiong and Yongjian Xu},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2012},
  volume={37 2},
  pages={
          204-11
        }
}
WHAT IS KNOWN AND OBJECTIVE   Inhaled long-acting beta-agonists have been licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late 1990s, and they improve lung function and symptoms of dyspnoea. However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations. METHODS MEDLINE, EMBASE, CINAHL and the Cochrane trials… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

The long-acting β2-adrenoceptor agonist olodaterol attenuates pulmonary inflammation

VIEW 1 EXCERPT
CITES BACKGROUND

Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

VIEW 1 EXCERPT
CITES BACKGROUND